Real-World Effectiveness of Omalizumab Treatment in Adult Asthma Patients
Yonsei Medical Journal · 2025
DOI: 10.3349/ymj.2024.0320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Yonsei Medical Journal, 2025. Verfasst von Jae-Hyuk Jang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy & Clinical Immunology, Ajou University School of Medicine, Suwon, Korea. Hauptthemen laut MEDLINE: Omalizumab, Asthma, Anti-Asthmatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health & Welfare.
Abstract (Originalsprache)
PURPOSE: Omalizumab improves clinical outcomes for patients with severe asthma (SA), but its long-term effectiveness and potential biomarkers for predicting patient response require further investigation. This study aimed to evaluate the real-world effectiveness of omalizumab in treating SA and to identify potential biomarkers for predicting a favorable treatment response. MATERIALS AND METHODS: Clinical outcomes were compared between asthma patients receiving omalizumab (omalizumab group) and those on inhaled corticosteroid with long-acting beta-agonist (ICS-LABA) alone (ICS-LABA group). Propensity score matching and Cox proportional hazards model were used to calculate hazard ratios (HRs). Study outcomes included severe asthma exacerbation (SAE), incompletely controlled asthma, intravenous (IV) corticosteroid use, and asthma-related hospitalization. Incompletely controlled asthma was defined by blood eosinophil counts ≥150 cells/µL, fractional exhaled nitric oxide (FeNO) ≥25 ppb, forced expiratory volume in one second (FEV1%) 50% reduction in systemic corticosteroid dose) exhibited decreased blood neutrophil counts but increased FEV1% and serum total IgE levels compared with the treatment-unfavorable group. CONCLUSION: Omalizumab treatment effectively reduces SAE and improves lung function and asthma control. Blood neutrophil counts and serum total IgE may be potential biomarkers for predicting favorable responses to omalizumab treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy & Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
- Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.
- Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA.
- Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA.
- Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
- Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea. veritas@ajou.ac.kr.
ORCID-Profile: Jae-Hyuk Jang, ChulHyoung Park, Chungsoo Kim, Youngsoo Lee, Eunyoung Lee, Rae Woong Park, Hae-Sim Park
Förderung
- Korea Health Industry Development Institute
- Ministry of Health & Welfare
Zitieren
APA
Jang, J. H., Park, C., Kim, C., Lee, Y., Lee, E., Park, R. W., & Park, H. S. (2025). Real-World Effectiveness of Omalizumab Treatment in Adult Asthma Patients. Yonsei Medical Journal. https://doi.org/10.3349/ymj.2024.0320
Vancouver
Jang JH, Park C, Kim C, Lee Y, Lee E, Park RW, et al. Real-World Effectiveness of Omalizumab Treatment in Adult Asthma Patients. Yonsei Medical Journal. 2025. doi:10.3349/ymj.2024.0320
BibTeX
@article{Jang2025,
author = {Jang, Jae-Hyuk and Park, ChulHyoung and Kim, Chungsoo and Lee, Youngsoo and Lee, Eunyoung and Park, Rae Woong and Park, Hae-Sim},
title = {Real-World Effectiveness of Omalizumab Treatment in Adult Asthma Patients},
journal = {Yonsei Medical Journal},
year = {2025},
doi = {10.3349/ymj.2024.0320}
}
EUVIMED